Evidence map›Paper›PMID 35445820›Full record

Trial reportDiabetologia2022

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.

Simke W Waijer, Priya Vart, David Z I Cherney, Glenn M Chertow, Niels Jongs, Anna Maria Langkilde, Johannes F E Mann, Ofri Mosenzon, John J V McMurray, Peter Rossing and 5 more

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03036150 phase3completednot on this map

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

TypeinterventionalSponsorAstraZenecaRan2017 to 2020Enrolled4,304ConditionsChronic Kidney DiseaseArmsDapagliflozin, Placebo
NCT06890143 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2025 to 2027Enrolled44ConditionsPediatric Hereditary Kidney DiseasesArmsDapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Risk-directed management of chronic kidney disease.Nature reviews. Nephrology · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 10 countries.

Simke W WaijerDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0003-1717-0463
Priya VartDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0001-5576-820X
David Z I CherneyDepartment of Medicine, Division of Nephrology, University Health Network and University of Toronto, Toronto, Canada.ORCID 0000-0003-4164-0429
Glenn M ChertowDepartments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-7599-0534
Niels JongsDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID 0000-0002-0882-3656
Anna Maria LangkildeLate-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Johannes F E MannKfH Kidney Center Munich, Germany, and Department of Medicine 4, University of Erlangen-Nürnberg, Erlangen, Germany.
Ofri MosenzonDiabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.
John J V McMurrayInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-6317-3975
Peter RossingSteno Diabetes Center Copenhagen, Gentofte, Denmark.ORCID 0000-0002-1531-4294
Ricardo Correa-RotterThe National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico.ORCID 0000-0003-0100-8285
Bergur V StefanssonLate-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Robert D TotoDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9531-1749
David C WheelerDepartment of Renal Medicine, University College London, London, UK.ORCID 0000-0003-0745-3478
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. h.j.lambers.heerspink@umcg.nl.ORCID 0000-0002-3126-3730
University Medical Center Groningen · NLAstraZeneca (Sweden) · SEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHebrew University of Jerusalem · ILInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXSouthwestern Medical Center · USStanford University · USUniversity College London · GBUniversity Health Network · CAUniversity of Copenhagen · DKUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisIn the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney disease, hospitalised heart failure or cardiovascular death, and death from all causes in patients with chronic kidney disease (CKD) with or without type 2 diabetes. Patients with more severe CKD are at higher risk of kidney failure, cardiovascular events and all-cause mortality. In this post hoc analysis, we assessed the efficacy and safety of dapagliflozin according to baseline Kidney Disease Improving Global Outcomes (KDIGO) risk categories.

methodsDAPA-CKD was a double-blind, placebo-controlled trial that randomised patients with an eGFR of 25-75 ml min

resultsOf the 4304 participants in the DAPA-CKD study, 619 (14.4%) were moderately high risk, 1349 (31.3%) were high risk and 2336 (54.3%) were very high risk when categorised by KDIGO risk categories at baseline. Dapagliflozin reduced the hazard of the primary composite (HR 0.61; 95% CI 0.51, 0.72) and secondary endpoints consistently across KDIGO risk categories (all p for interaction >0.09). Absolute risk reductions for the primary outcome were also consistent irrespective of KDIGO risk category (p for interaction 0.26). Analysing patients with and without type 2 diabetes separately, the relative risk reduction with dapagliflozin in terms of the primary outcome was consistent across subgroups of KDIGO risk categories. The relative frequencies of adverse events and serious adverse events were also similar across KDIGO risk categories. CONCLUSION/INTERPRETATIONS: The consistent benefits of dapagliflozin on kidney and cardiovascular outcomes across KDIGO risk categories indicate that dapagliflozin is efficacious and safe across a wide spectrum of kidney disease severity.

trial registrationClinicalTrials.gov NCT03036150.

fundingThe study was funded by AstraZeneca.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Heart FailureKidney Failure, ChronicRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlomerular Filtration RateGlucosidesHumansKidneyBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsAlbuminuriaDapagliflozineGFRKDIGO risk categoriesKidney outcomeSGLT2 inhibitor

Identifiers

PMID35445820
PMCPMC9174107
OpenAlexW4224235109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.